Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
In Italy, reimbursement restrictions regarding palivizumab prophylaxis approved in 2016 have been revoked in 2017, restoring use in infants with Gestational Age (GA) >29 weeks. Respiratory Syncytial Virus (RSV) hospitalisations and prevalence of palivizumab use in infants aged <6 months during...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
BMJ Publishing Group,
2021-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|